menu
    • menu
    [{"orgOrder":0,"company":"Diakonhjemmet Hospital","sponsor":"Oslo University Hospital | Martina Hansen's Hospital | South-Eastern Norway Regional Health Authority | Akershus University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NORWAY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Triamcinolone Hexacetonide","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Diakonhjemmet Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diakonhjemmet Hospital \/ Oslo University Hospital | Martina Hansen's Hospital | South-Eastern Norway Regional Health Authority | Akershus University Hospital","highestDevelopmentStatusID":"11","companyTruncated":"Diakonhjemmet Hospital \/ Oslo University Hospital | Martina Hansen's Hospital | South-Eastern Norway Regional Health Authority | Akershus University Hospital"},{"orgOrder":0,"company":"Anika Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"||CD44","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Anika Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Anika Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anika Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Triamcinolone Hexacetonide

    Menu

    Triamcinolone Hexacetonide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Anika Therapeutics

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Anika Therapeutics

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Hyaluronate,Triamcinolone Hexacetonide

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Anika’s Cingal® Successfully Achieves Primary Endpoint in Third Phase III Study

                            Details : Cingal (sodium hyaluronate) combination product of cross-linked hyaluronic acid (HA) proven to provide long lasting pain relief through 6 months plus TH steroid to provide fast, short-term pain relief.

                            Product Name : Cingal

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 01, 2022

                            Lead Product(s) : Sodium Hyaluronate,Triamcinolone Hexacetonide

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Diakonhjemmet Hospital

                            Country arrow
                            Luxepack
                            Not Confirmed

                            Diakonhjemmet Hospital

                            Country arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Triamcinolone Hexacetonide

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Oslo University Hospital | Martina Hansen's Hospital | South-Eastern Norway Regional Health Authority | Akershus University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Norwegian Trial Comparing Treatment Strategies for Carpal Tunnel Syndrome

                            Details : Triamcinolone Hexacetonide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Carpal Tunnel Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 01, 2022

                            Lead Product(s) : Triamcinolone Hexacetonide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Oslo University Hospital | Martina Hansen's Hospital | South-Eastern Norway Regional Health Authority | Akershus University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth